Ezetimibe: Dosage, Indications, and Contraindications
Ezetimibe is dosed at 10 mg orally once daily, with or without food, and serves as a critical add-on therapy to statins when LDL-C targets are not met, or as monotherapy when statins cannot be used. 1
Recommended Dosage
- Standard dose: 10 mg once daily (administered with or without food) 1
- If a dose is missed, take it as soon as possible; do not double the next dose 1
- Timing with bile acid sequestrants: Administer ezetimibe at least 2 hours before or 4 hours after bile acid sequestrants to avoid reduced absorption 1
- LDL-C should be assessed as early as 4 weeks after initiation 1
Important note: While one study suggested 5 mg (half of a 10-mg tablet) may be clinically equivalent 2, the FDA-approved and guideline-recommended dose remains 10 mg daily 1.
Indications
Primary Indications (FDA-Approved) 1:
In combination with a statin:
- Adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)
- Pediatric patients ≥10 years with HeFH
- Adults and pediatric patients ≥10 years with homozygous familial hypercholesterolemia (HoFH)
As monotherapy:
- When additional LDL-C lowering therapy is not possible (e.g., statin intolerance)
- Adults and pediatric patients ≥9 years with homozygous familial sitosterolemia
In combination with fenofibrate:
- Adults with mixed hyperlipidemia
Guideline-Based Use 3:
Add ezetimibe to maximally tolerated statin when:
- Very high cardiovascular risk patients with LDL-C ≥70 mg/dL (1.8 mmol/L) despite statin therapy
- High-risk patients failing to meet LDL-C targets (ranging from 55-135 mg/dL depending on risk stratification)
- Primary prevention when maximum tolerated statin dose does not achieve >40% non-HDL-C reduction after 3 months
The European Society of Cardiology (ESC) 2019 guidelines provide the strongest recommendation: combination with ezetimibe is recommended when LDL goals are not achieved with maximum tolerated statin dose (Class I recommendation for secondary prevention) 3.
Emerging evidence: The EWTOPIA 75 study demonstrated that ezetimibe monotherapy reduces ASCVD events in patients ≥75 years without prior coronary disease, suggesting particular benefit in elderly populations where cholesterol absorption efficiency increases with age 4.
Contraindications
Absolute Contraindications 1:
- Hypersensitivity to ezetimibe or any excipient
- When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe is contraindicated if those agents are contraindicated for the patient (refer to their prescribing information)
Warnings and Precautions 1:
Liver enzyme abnormalities:
- Increases in serum transaminases have been reported
- Perform liver enzyme testing as clinically indicated
- Consider withdrawal if ALT or AST ≥3× ULN persist
Skeletal muscle effects (myopathy/rhabdomyolysis):
- Most post-marketing reports of rhabdomyolysis occurred in patients taking concomitant statins or fibrates
- If myopathy is suspected, discontinue ezetimibe and other concomitant medications
Drug interactions to monitor:
- Cyclosporine: Higher ezetimibe exposures observed; monitor cyclosporine levels carefully 5
- Bile acid sequestrants: Significantly decrease ezetimibe bioavailability; separate administration by several hours 5
- Gemfibrozil and fenofibrate: Increase ezetimibe bioavailability, though clinical significance is minor 5
Clinical Pearls
Advantages of ezetimibe:
- Minimal systemic absorption leads to few drug interactions (not metabolized by CYP450) 6, 5
- Safety profile similar to placebo when used as monotherapy 7
- Provides 15-20% additional LDL-C reduction when added to statins 3, 7
- May be particularly effective in elderly patients due to increased cholesterol absorption efficiency with age 4
Common pitfall: Do not assume ezetimibe is less effective than statin intensification. Recent evidence suggests moderate-intensity statin plus ezetimibe may offer similar LDL-C reduction with better tolerability and adherence compared to high-intensity statin monotherapy, particularly in elderly patients 8, 9.
Adherence advantage: The combination of moderate-intensity statin with ezetimibe showed only 0.7% incidence of statin-associated muscle symptoms versus 5.7% with high-intensity statin monotherapy in elderly ASCVD patients 9.